
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is well-positioned in the market with strong and successful products in the areas of HIV, hepatitis, and oncology. The company's pipeline, particularly in the areas of CAR-T cell therapy and oncology, has the potential to bring in significant revenue in the future. However, there are risks to consider, including competition, pricing pressures, and potential legal issues with patents. Despite these risks, the company's commitment to sustainability and transparency, strong partnerships and acquisitions, and diverse product portfolio make it a strong investment opportunity.
Bears say
Gilead Sciences is poised for long-term growth potential thanks to its strong presence in the HIV and hepatitis treatment markets and its promising oncology pipeline. However, the recent acquisition of Trodelvy comes with risks and the company's questionable track record in oncology M&A may cause investors to approach with caution. With strong cash flows from their existing franchises and potential catalysts in the short term, the outlook for Gilead Sciences is mixed, but promising.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares